FDA Fast Track designation for Aravax’s novel peptide immunotherapy PVX108 marks a significant milestone in expanding disease-modifying options for peanut allergy.
Five major FDA Priority Review decisions are scheduled for September 2026, targeting rare genetic neurological conditions, FGFR2-mutated cholangiocarcinoma, and adolescent obstructive hypertrophic ...
Higher rate of treatment success seen with omalizumab in intention-to-treat analysis, but not in per-protocol analysis.
HealthDay News — There are considerable gaps in low-density lipoprotein cholesterol (LDL-C) control, especially among adults with established atherosclerotic cardiovascular disease (ASCVD), according ...
Expanded indiction allows earlier radioligand therapy in PSMA-positive metastatic hormane-sensitive prostate cancer based on phase 3 PSMAddition trial data.
Nearly 1 in 6 parents say their 18- to 25-year-old does not handle any basic health care responsibilities on their own ...
Significant improvement seen in clinical efficacy with press-needle therapy; therapy plus medication superior to medication alone ...
The FTC alleges most consumers never get a consultation, instead, they are billed and enrolled in recurring subscription plans shortly after submitting the form.
Backed by phase 3 Luminous trial data, Gwyn Lo is now FDA-approved and will be available to patients later this year.
Cancer progression within 36 months of combination therapy identified patients with overall survival of less than 2 years.
Shionogi’s oral main protease inhibitor Xocova (ensitrelvir) is now available in the US to reduce the risk of symptomatic ...
Despite noting the high unmet need in Duchenne muscular dystrophy, the FDA panel concluded that trial data lacked substantial evidence of the therapy's effectiveness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results